The S&P 500 has dropped 3.8% since the end of July, but that's nothing compared to the losses we've seen from biotech stocks.
In fact, this week's latest pullback has many biotech stocks in bear market territory.
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM -
The S&P 500 has dropped 3.8% since the end of July, but that's nothing compared to the losses we've seen from biotech stocks.
In fact, this week's latest pullback has many biotech stocks in bear market territory.
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM -
The S&P 500 has dropped 3.8% since the end of July, but that's nothing compared to the losses we've seen from biotech stocks.
In fact, this week's latest pullback has many biotech stocks in bear market territory.
Here's just how far they've fallen...
By Kyle Anderson, Associate Editor, Money Morning • @KyleAndersonMM -
Biotech stocks have gotten crushed in recent weeks, with the Nasdaq Biotechnology Index falling 15.5% in the last month and 25% from its July highs.
And while many investors are taking their money to the sideline, this is actually a great time to invest in biotech ETFs with 2016 in mind.
Here's the biotech ETF we're recommending now...